The first non-hormonal drug to treat hot flashes looks like it will hit the US market imminently, with approval of fezolintant anticipated as early as February 22.
If you are wondering why Japan’s Astellas Pharma can put a date on such things, I’ll tell you.
You know what to do.
Keep reading with a 7-day free trial
Subscribe to Hotflash Inc to keep reading this post and get 7 days of free access to the full post archives.